Go to the list of all blogs
M. Benett's Avatar
published in Blogs
May 21, 2026
Onto Innovation (ONTO) Stock: -11% Dip Over 30 Days Despite +17% Quarterly Gain

Onto Innovation (ONTO) Stock: -11% Dip Over 30 Days Despite +17% Quarterly Gain

Key Takeaways

  • ONTO stock declined approximately 11% over the past 30 days, moving from around 295 to 263 amid broader semiconductor sector pressures.
  • Over the past quarter, the stock posted a gain of about 17%, reflecting recovery from earlier levels near 225.
  • Short-term price movement was driven by sector rotation and macroeconomic sensitivity in the semiconductor equipment space.
  • Quarterly performance benefited from sustained demand for advanced process control solutions in chip manufacturing.
  • Investor sentiment shifted as high interest rates continued to weigh on growth-oriented technology names.
  • Key influencing factors included earnings visibility, industry supply chain dynamics, and overall market risk appetite.

Company Overview for Onto Innovation Inc. (ONTO)

Onto Innovation Inc. provides process control solutions for the semiconductor and electronics manufacturing industries. The company develops and sells metrology and inspection systems that help chipmakers improve yield and quality during fabrication. Its core business model centers on hardware and software tools used in advanced packaging, lithography, and thin-film measurement. Positioned in the semiconductor capital equipment sector, Onto Innovation competes with larger players while benefiting from the long-term growth in artificial intelligence, high-performance computing, and advanced node production. Strong exposure to capital spending cycles in the semiconductor industry directly influences recent stock behavior, as investors closely track order trends and technology adoption rates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ONTO Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, ONTO shares declined roughly 11%, moving from approximately 295 to 263. The price action was relatively steady with moderate volatility, showing a consistent downward bias rather than sharp daily swings. The movement appeared trend-driven, influenced by sector-wide selling in technology equities.

Over the last quarter, the stock rose approximately 17%, advancing from levels near 225 to 263. Performance was more constructive, with periods of range-bound trading followed by upward momentum in earlier months. The quarterly trend reflected broader recovery in semiconductor demand, though tempered by recent pullbacks. From what I see, this contrast highlights how sector rotation can quickly shift momentum even in fundamentally sound names.

What Drove ONTO Stock Price in the Last 30 Days

The primary catalyst behind the 30-day decline was rotation out of high-valuation semiconductor equipment stocks as investors reassessed growth prospects amid persistent high interest rates. Sector sentiment weakened as macro concerns around inflation and potential delays in capital expenditure plans resurfaced. No major company-specific earnings release occurred in the immediate window, but broader market trends in technology equities exerted downward pressure. Analyst commentary remained largely neutral, with limited upgrades or downgrades noted during the period. The stock exhibited limited volatility but followed the general direction of peer companies in the process control segment.

What Drove ONTO Stock Performance Over the Last Quarter

Over the full quarter, sustained demand for advanced metrology tools supporting next-generation chip production provided the main positive narrative. Industry developments, including continued investment in artificial intelligence infrastructure and advanced packaging technologies, supported investor optimism. Macroeconomic conditions, particularly expectations around monetary policy easing, contributed to the overall recovery from earlier lows. Institutional flows into semiconductor-related names added further support during the period. Competitive positioning in high-growth areas such as lithography overlay measurement helped reinforce the quarterly advance, outweighing shorter-term headwinds.

Exploring Automated Trading Options

One tool I find useful when evaluating names like this is Tickeron’s Trending AI Robots page. It showcases a curated selection of top-performing artificial intelligence trading bots. Tickeron offers hundreds of AI trading bots that analyze and trade thousands of tickers across multiple markets. Only the strongest and most relevant bots based on recent performance metrics appear in this section. Strategies range from short-term momentum approaches to longer-term trend-following systems, with varying timeframes and risk parameters. The page provides transparent performance data to help users explore automated trading options suited to different market conditions. I often visit the Trending AI Robots section to review current offerings when looking for additional perspective on market dynamics.

ONTO Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor upcoming quarterly earnings for updates on order backlog and guidance. Industry trends in semiconductor capital spending, particularly for advanced nodes and packaging, remain important. Macroeconomic indicators such as interest rate decisions and inflation data will likely influence sentiment. Strategic developments including new product launches or partnerships in process control technology should also be tracked. Potential risks include supply chain disruptions and shifts in customer capital expenditure plans. I’m watching this closely as the next earnings release could clarify whether the recent pullback creates an entry point or signals further caution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ONTO

ONTO's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ONTO turned positive on September 21, 2026. Looking at past instances where ONTO's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 18, 2026. You may want to consider a long position or call options on ONTO as a result. In 82 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

ONTO moved above its 50-day moving average on September 25, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ONTO crossed bullishly above the 50-day moving average on September 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.

Following a +6.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONTO advanced for three days, in 267 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONTO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

The Aroon Indicator for ONTO entered a downward trend on September 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 31 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ONTO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.369) is normal, around the industry mean (8.078). P/E Ratio (108.142) is within average values for comparable stocks, (161.623). Projected Growth (PEG Ratio) (0.817) is also within normal values, averaging (0.801). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (10.787) is also within normal values, averaging (27.897).

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Lam Research Corp (NASDAQ:LRCX), Applied Materials (NASDAQ:AMAT), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 63.66B. The market cap for tickers in the group ranges from 326.86K to 671.68B. ASML holds the highest valuation in this group at 671.68B. The lowest valued company is AVSR at 326.86K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 4%. For the same Industry, the average monthly price growth was 12%, and the average quarterly price growth was 13%. INTT experienced the highest price growth at 28%, while SMTK experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was 15%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 34
Price Growth Rating: 42
SMR Rating: 71
Profit Risk Rating: 59
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
ONTO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in developing process control systems and offers process control, combining global scale with an expanded portfolio of technologies

Industry ElectronicProductionEquipment

Industry
N/A
Address
16 Jonspin Road
Phone
+1 978 253-6200
Employees
1615
Web
https://www.ontoinnovation.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.